Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Exosome MicroRNA Evaluation for Biomarker Development in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy

EF 2020-21

Résumé
Renal cell carcinoma is the most common type of cancer affecting the kidneys and its incidence is increasing. It is frequently diagnosed in advanced stages and upon diagnosis of metastatic renal cell carcinoma (mRCC), systemic treatment is initiated. The standard of care for mRCC is now immunotherapy in the form of dual immune checkpoint inhibitors (ICI) or in combination with targeted therapy. These drugs work by activating the immune system to target cancer cells. Though overall response rates are excellent, unfortunately many patients do not respond to these treatments. Therefore an important unmet need in the treatment of mRCC is the development of biomarkers to predict who will best respond to ICI. Exosomes are small vesicles which are released from cancer cells and carry a variety of components, including microRNAs (miRNAs). MiRNAs are small non-coding RNA which impact gene expression and can modulate the tumour cells' environment. Exosome miRNAs have been isolated from blood of patients with mRCC and have been shown to have prognostic value and associated with worse clinical outcomes. As proof of concept, we have successfully isolated exosomes from 4 blood samples of patients with mRCC and found a differential expression of at least 3 key miRNAs. MiRNAs have not been studied for use as predictive biomarkers in this new era of mRCC treatment with ICI. Based on this rationale and promising preliminary results, we propose the first study of its kind, to our knowledge, to utilize exosome miRNAs from blood samples of patients with mRCC for full characterization and clinical correlation of outcomes with ICI. This information can help physicians identify the best treatment, amongst multiple options, for each patient thus improving outcomes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449378
Name
Soleimani Maryam
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exosome MicroRNA Evaluation for Biomarker Development in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Cancer; Exosomes; Immunotherapy; Microrna; Renal Cell Carcinoma; Response; Survival; Translational; Treatment
Abstract
Renal cell carcinoma is the most common type of cancer affecting the kidneys and its incidence is increasing. It is frequently diagnosed in advanced stages and upon diagnosis of metastatic renal cell carcinoma (mRCC), systemic treatment is initiated. The standard of care for mRCC is now immunotherapy in the form of dual immune checkpoint inhibitors (ICI) or in combination with targeted therapy. These drugs work by activating the immune system to target cancer cells. Though overall response rates are excellent, unfortunately many patients do not respond to these treatments. Therefore an important unmet need in the treatment of mRCC is the development of biomarkers to predict who will best respond to ICI. Exosomes are small vesicles which are released from cancer cells and carry a variety of components, including microRNAs (miRNAs). MiRNAs are small non-coding RNA which impact gene expression and can modulate the tumour cells' environment. Exosome miRNAs have been isolated from blood of patients with mRCC and have been shown to have prognostic value and associated with worse clinical outcomes. As proof of concept, we have successfully isolated exosomes from 4 blood samples of patients with mRCC and found a differential expression of at least 3 key miRNAs. MiRNAs have not been studied for use as predictive biomarkers in this new era of mRCC treatment with ICI. Based on this rationale and promising preliminary results, we propose the first study of its kind, to our knowledge, to utilize exosome miRNAs from blood samples of patients with mRCC for full characterization and clinical correlation of outcomes with ICI. This information can help physicians identify the best treatment, amongst multiple options, for each patient thus improving outcomes.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Soleimani, Maryam
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~